The canine papillomavirus and gamma HPV E7 proteins use an alternative domain to bind and destabilize the retinoblastoma protein.
The high-risk HPV E6 and E7 proteins cooperate to immortalize primary human cervical cells and the E7 protein can independently transform fibroblasts in vitro, primarily due to its ability to associate with and degrade the retinoblastoma tumor suppressor protein, pRb. The binding of E7 to pRb is mediated by a conserved Leu-X-Cys-X-Glu (LXCXE) motif in the conserved region 2 (CR2) of E7 and this domain is both necessary and sufficient for E7/pRb association. In the current study, we report that the E7 protein of the malignancy-associated canine papillomavirus type 2 encodes an E7 protein that has serine substituted for cysteine in the LXCXE motif. In HPV, this substitution in E7 abrogates pRb binding and degradation. However, despite variation at this critical site, the canine papillomavirus E7 protein still bound and degraded pRb. Even complete deletion of the LXSXE domain of canine E7 failed to interfere with binding to pRb in vitro and in vivo. Rather, the dominant binding site for pRb mapped to the C-terminal domain of canine E7. Finally, while the CR1 and CR2 domains of HPV E7 are sufficient for degradation of pRb, the C-terminal region of canine E7 was also required for pRb degradation. Screening of HPV genome sequences revealed that the LXSXE motif of the canine E7 protein was also present in the gamma HPVs and we demonstrate that the gamma HPV-4 E7 protein also binds pRb in a similar way. It appears, therefore, that the type 2 canine PV and gamma-type HPVs not only share similar properties with respect to tissue specificity and association with immunosuppression, but also the mechanism by which their E7 proteins interact with pRb.
Wang
Jingang
J
Department of Pathology, Georgetown University Medical School, Washington, D.C., USA.
Zhou
Dan
D
Prabhu
Anjali
A
Schlegel
Richard
R
Yuan
Hang
H
D020816:Amino Acid Motifs; D000595:Amino Acid Sequence; D000818:Animals; D001665:Binding Sites; D015153:Blotting, Western; D001859:Bone Neoplasms / Q000378:metabolism / Q000473:pathology; D004285:Dogs; D006801:Humans; D051379:Mice; D008969:Molecular Sequence Data; D012516:Osteosarcoma / Q000378:metabolism / Q000473:pathology; D027383:Papillomaviridae / Q000502:physiology*; D050725:Papillomavirus E7 Proteins / Q000235:genetics / Q000378:metabolism*; D030361:Papillomavirus Infections / Q000378:metabolism* / Q000473:pathology / Q000821:virology; D011485:Protein Binding; D017434:Protein Structure, Tertiary; D012333:RNA, Messenger / Q000235:genetics; D016160:Retinoblastoma Protein / Q000737:chemistry* / Q000235:genetics / Q000378:metabolism*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D017386:Sequence Homology, Amino Acid; D014407:Tumor Cells, Cultured
D050725:Papillomavirus E7 Proteins; D012333:RNA, Messenger; D016160:Retinoblastoma Protein; C059731:oncogene protein E7, Human papillomavirus type 16
Virology. 1996 Mar 15;217(2):542-53
8610446
J Virol. 2006 Jul;80(13):6621-8
16775349
Oncogene. 2006 Aug 28;25(38):5277-85
16936748
J Virol. 1992 Apr;66(4):2418-27
1312637
Virology. 2007 Mar 1;359(1):28-36
17034826
J Virol. 2002 Nov;76(21):10685-91
12368310
Mol Cell Biol. 1993 Feb;13(2):953-60
7678696
Virology. 2009 Feb 20;384(2):335-44
19007963
J Virol. 2001 Sep;75(17):7848-53
11483728
J Virol. 1994 Sep;68(9):6120-3
8057494
Virology. 1995 Dec 1;214(1):289-93
8525630
J Virol. 1984 Sep;51(3):872-5
6088809
J Virol. 1993 Apr;67(4):2402-7
8445736
Cancer Res. 2005 Dec 1;65(23):10854-61
16322232
J Virol. 1989 Jun;63(6):2650-6
2542578
J Gen Virol. 2009 Nov;90(Pt 11):2615-2621
19656968
J Biol Chem. 1994 Mar 4;269(9):6842-50
8120046
J Gen Virol. 1999 Feb;80 ( Pt 2):327-332
10073691
Cancer Detect Prev. 2008;32(1):15-22
18406069
EMBO J. 1989 Dec 20;8(13):4099-105
2556261
Virology. 2004 Jun 20;324(1):17-27
15183049
Int J Biochem Cell Biol. 2007;39(11):2006-11
17768080
Vaccine. 2001 Apr 6;19(20-22):2783-92
11282188
J Virol. 2001 Aug;75(15):6737-47
11435552
EMBO J. 1999 May 4;18(9):2449-58
10228159
J Biol Chem. 2006 Jan 6;281(1):578-86
16249186
J Virol. 2004 Nov;78(22):12698-702
15507660
Mol Biol Evol. 2007 Aug;24(8):1596-9
17488738
J Virol. 2007 Sep;81(18):9737-47
17609271
Nat Rev Cancer. 2007 Jan;7(1):11-22
17186016
J Virol. 1992 Dec;66(12):6893-902
1331501
Virology. 2009 Feb 20;384(2):324-34
19081593
EMBO J. 1988 Oct;7(10):3181-7
2460337
Nat Rev Cancer. 2002 May;2(5):342-50
12044010
J Biol Chem. 1990 Aug 5;265(22):12782-5
2198278
J Virol. 2004 Nov;78(21):11451-60
15479788
J Gen Virol. 1990 Apr;71 ( Pt 4):965-70
2157805
J Virol. 1988 May;62(5):1814-8
2965766
J Virol. 1992 Mar;66(3):1329-35
1310752
Nucleic Acids Res. 1994 Nov 11;22(22):4673-80
7984417
Oncogene. 2001 Nov 26;20(54):7888-98
11753671